At the ACRT Conference in Boston, an international forum focused on advancing translational cancer research and therapeutic innovation, QT Sense contributed to discussions cantered on improving how complex diseases are measured and understood. The conference brought together clinicians, researchers, and drug developers across oncology, with a strong emphasis on emerging technologies that can accelerate therapeutic breakthroughs. Representing QT Sense, Deepak, Chief Executive Officer, delivered an invited presentation focused on mechanistic study of ONC 201 on breast cancer cell line, highlighting how quantum sensing can transform drug discovery by enabling real-time measurement of dynamic biochemical processes.
Across the conference, it became clear that a major limitation in oncology research remains the reliance on endpoint assays, which fail to capture transient but critical biological signals such as oxidative stress and metabolic adaptation. Quantum Nuova addresses this gap by enabling continuous, non-destructive monitoring of free radical kinetics, providing a time-resolved readout of sub-cellular state and early drug response. The strong engagement from attendees reflected a growing demand for technologies that move beyond static measurements toward dynamic, functional insight. QT Sense was recognized as introducing a new measurement paradigm in oncology—one that complements molecular and imaging approaches by adding a critical temporal dimension to understanding disease and therapeutic response.
